Cork, Michael J.
Thaçi, Diamant
Eichenfield, Lawrence F.
Arkwright, Peter D.
Chen, Zhen
Thomas, Ryan B.
Kosloski, Matthew P.
Dubost-Brama, Ariane
Prescilla, Randy
Bansal, Ashish
Levit, Noah A. http://orcid.org/0000-0002-0797-5121
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-023-01016-9
161 52-Week Laboratory Safety Findings From an Open-Label Extension Study of Dupilumab in Adolescent Patients With Atopic Dermatitis (LIBERTY AD PED-OLE)
https://doi.org/10.1136/archdischild-2021-europaediatrics.161
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
https://doi.org/10.1007/s40257-020-00577-1
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 2 June 2023
Accepted: 15 August 2023
First Online: 26 September 2023
Declarations
:
: Michael J. Cork has been a consultant and/or investigator for Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L’Oréal, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals Inc., and Sanofi. Diamant Thaçi has been a consultant/advisory board member and/or investigator for AbbVie, Almirall, Amgen, Beiersdorf, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Galderma, Janssen-Cilag, Kyowa-Kirin, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Roche-Posay, Samsung, Sanofi, Sun Pharma, and UCB. Lawrence F. Eichenfield has received honoraria for consulting services from AbbVie, Aslan, BMS, Dermavant, Eli Lilly, Forté, Galderma, Incyte, Janssen, Otsuka, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi and has received study support (to institution) from AbbVie, Arcutis, Bausch, Castle Biosciences, Dermavant, Galderma, Incyte, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi. Peter D. Arkwright has been an investigator for Regeneron Pharmaceuticals Inc. and has received a research grant from and been an advisor for Sanofi. Zhen Chen, Ryan B. Thomas, Matthew P. Kosloski, and Ashish Bansal are employees and shareholders of Regeneron Pharmaceuticals Inc. Ariane Dubost-Brama and Randy Prescilla are employees of Sanofi, and may hold stock and/or stock options in the company. Noah A. Levit is a former employee and shareholder of Regeneron Pharmaceuticals Inc., currently an employee of the Dermatology Physicians of Connecticut, Fairfield, CT, USA.
: The study was conducted following the ethical principles derived from the Declaration of Helsinki, the International Conference on Harmonisation guidelines, Good Clinical Practice, and local applicable regulatory requirements. Written informed consent was obtained from all patients and the patients’ parents/guardians prior to commencement of any study treatment. At each study site, the protocol, informed-consent form, and patient information were approved by an institutional review board and independent ethics committee.